Table 1 Risk stratification by clinical risk factors: Clinical T-stage, Gleason score, and presenting PSA. Locally advance prostate cancer includes high-risk localised patients, as defined by NCCN [16]
From: Joint models for dynamic prediction in localised prostate cancer: a literature review
Risk level | Clinical T-stage | Gleason Grading Group | Presenting PSA | Condition to be met |
|---|---|---|---|---|
Low risk | T1-T2a | 1 | <  10 ng/mL | All three |
Intermediate risk | T2b-c | 2 or 3 | 10-20 ng/mL | Any |
High risk | T3a | 4 or 5 | > 20 ng/mL | Any |